First, a CSF-based dichotomous measure of Aβ-pathology was used for dementia participants, since (per protocol) the majority of patients with dementia did not undergo Aβ-PET, which may have led to a less accurate investigation of Aβ effects on tau in the total CI group. The gene discussed is MAPT; the disease is dementia.